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ABSTRACT
Ionizing radiation is an important treatment
modality for a variety of malignant conditions.
However, development of radiation-induced
skin changes is a significant adverse effect
of radiation therapy (RT). Cutaneous
repercussions of RT vary considerably in
severity, course, and prognosis. When they do
occur, cutaneous changes to RT are commonly
graded as acute, consequential-late, or chronic.
Acute reactions can have severe sequelae that
impact quality of life as well as cancer
treatment. Thus, dermatologists should be
informed about these adverse reactions, know
how to assess their severity and be able to
determine course of management. The majority
of measures currently available to prevent these
acute reactions are proper skin hygiene and
topical steroids, which limit the severity and
decrease symptoms. Once acute cutaneous
reactions develop, they are treated according
to their severity. Treatments are similar to those
used in prevention, but incorporate wound care
management that maintains a moist
environment to hasten recovery. Chronic
changes are a unique subset of adverse
reactions to RT that may develop months to
years following treatment. Chronic radiation
dermatitis is often permanent, progressive, and
potentially irreversible with substantial impact
on quality of life. Here, we also review the
etiology, clinical manifestations, pathogenesis,
prevention, and management of late-stage
cutaneous reactions to radiotherapy, including
chronic radiation dermatitis and
radiation-induced fibrosis.
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INTRODUCTION
Ionizing radiation (IR) is used to treat a variety
of malignant conditions and is used to palliate
metastatic disease. However, the development
of radiation-induced skin changes is a
significant adverse effect of radiation therapy
(RT). Skin reactions to radiation are largely a
function of technique, total dose, volume, and
individual variations in treatment [1, 2]. While
advances in technology and changes to
therapeutic regimens have reduced the burden
of cutaneous reactions to RT, radiation
dermatitis remains a significant adverse effect
of radiotherapy.
Cutaneous repercussions of RT vary
considerably in severity, course, and prognosis.
When they do occur, cutaneous changes to RT
are commonly graded as acute,
consequential-late, or chronic [3]. Acute
changes include erythema and pain and occur
within 90 days [3]. Even with modern
radiotherapy techniques, approximately 85%
of patients will experience a moderate to
severe acute skin reaction in exposed areas [4].
Severe acute reactions may lead to blistering,
erosions, and ulceration [5], which can lead to
premature interruption of RT and potentially
negatively influence cancer control and
prognosis. Alternatively, the skin may appear
relatively normal for months to years following
RT, when chronic radiation dermatitis develops
[3]. Chronic radiation dermatitis is permanent,
progressive, and irreversible and has substantial
impact on quality of life [5]. Thus, it is
important for dermatologists to be able to
recognize the adverse reactions to IR in order
to assess the severity of disease and to assist in
the management of these conditions. This
review of cutaneous repercussions of RT is
based on previously conducted studies and
does not involve any new studies of human or
animal subjects performed by the authors.
CLINICAL MANIFESTATIONS
Acute Radiation Dermatitis
Acute radiation dermatitis is one of the most
common reactions to RT and usually occurs
within 90 days of exposure. The severity of
reaction ranges from mild erythema to moist
desquamation and ulceration (Table 1) [6, 7].
The reaction typically starts within 1–4 weeks
after starting radiation treatment and persists
during the radiation treatment period [8]. Acute
radiation dermatitis is likely to heal with mild
cutaneous changes.
The severity of disease can be graded on a
scale of 1–4 according to the National Cancer
Institute (Table 2). Acute reactions start with
erythema, edema, pigmentary changes and
depilation that correlate with the amount of
radiation exposure. Grade 1 changes include dry
desquamation with a generalized erythema
(Fig. 1). Pruritus, epilation, scaling and
depigmentation can also occur. With grade 2,
there is brisk erythema or localized focal
sloughing of the epidermis (Fig. 2). These
reactions lead to moist desquamation confined
to the skin folds once the cumulative radiation
dose reaches 40 Gy or more [9]. With moist
desquamation, the epidermal layer is lost and
there is a high propensity for infection. The
reaction peaks in 1–2 weeks with subsequent
healing. Patients can experience increased pain
due to exposure of nerve endings. Grade 3
presents with extensive moist desquamation
outside of skin folds (Fig. 3). With grade 4,
ulcerations, hemorrhage and skin necrosis
occur that in some cases does not resolve,
leading to the late-consequential changes of
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acute dermatitis that include ulcerations and
fibrosis.
Reepithelialization usually starts within
10 days, but can be prolonged with exposure
to radiosensitizing drugs especially platinum
based chemotherapy. Additional findings that
may occur with acute radiation dermatitis
include comedo reactions of whiteheads and
blackheads in head and neck cancers.
Pseudorecidives (keratosis-like lesions) and
transient hair loss may progress to
permanent hair loss if follicular fibrosis
occurs [10].
Radiation Burns
Radiation burns, although rare with current
treatment modalities, can occur with high-dose
exposure to x-rays during interventional
Table 1 Dose-dependent acute cutaneous ﬁndings after local radiation exposure [7]
Observed acute skin reaction Radiation dose (Gy) Onset of ﬁndings
Transient erythema 2 Hours
Faint erythema and epilation 6–10 7–10 days
Deﬁned erythema and hyperpigmentation 12–20 2–3 weeks
Dry desquamation 20–25 3–4 weeks
Moist desquamation 30–40 4 weeks or more
Ulceration [40 6 weeks or more
Table 2 Classiﬁcation of acute radiation dermatitis
Grade




Moderate to brisk erythema or patchy
moist desquamation, mostly
conﬁned to skin folds and creases;
moderate erythema
Moist desquamation other
than skin folds; pitting
edema, bleeding from minor
trauma or abrasion




According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 3
Fig. 1 Grade 1 acute radiation dermatitis. Reproduced
from Mesı´a et al. [132] under open-access article dis-
tributed under the terms of the creative commons
attribution license. Copyright 2009
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radiology procedures or with RT [11].
Management of these lesions is difficult
because of the inability to differentiate
injured tissue from uninjured tissue [12, 13],
the unpredictable inflammatory waves that can
come weeks to years after tissue injury, and the
occurrence of opiate-resistant pain. [9].
Radiation Recall
Radiation recall is an acute inflammatory reaction
confined to an area previously exposed to
radiation after a chemotherapeutic agent or
other medication. Clinically, radiation recall
manifests with maculopapular eruptions, dry
desquamation, pruritus, swelling and
ulcerations. The incidence has been reported to
occur in up to 6% of individuals undergoing RT,
but reactions are drug-specific and can occur
weeks to months after the original RT and
subsequent chemotherapeutic administration
[14]. However, the majority of reactions occur
when the drug has been administered within
2 months of RT [15]. Radiation recall is most
frequently associated with traditional
chemotherapeutic agents including
anthracyclines, taxanes, and antimetabolites
[14], but reactions have been reported with
EGFR inhibitors, BRAF tyrosine kinase inhibitors
[16] and other non-chemotherapeutic agents (see
Table 3) [14, 15].
Fig. 2 Grade 2 acute radiation dermatitis. a Radiation
dermatitis of the breast with moist desquamation limited to
the inframammary fold. b Radiation dermatitis with
moderate erythema and scaly dry desquamation.
a Reprinted from Journal of the American Academy of
Dermatology, 54, Sharon R. Hymes, Eric A. Strom,
Caroline Fife, Radiation dermatitis: Clinical presentation,
pathophysiology, and treatment 2006, 28–46, Copyright
(2006), with permission from Elsevier
Fig. 3 Grade 3 acute radiation dermatitis with conﬂuent
moist desquamation. Reprinted from Journal of the
American Academy of Dermatology, 54, Sharon R. Hymes,
Eric A. Strom, Caroline Fife, Radiation dermatitis: Clinical
presentation, pathophysiology, and treatment 2006,
28–46, Copyright (2006), with permission from Elsevier
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Chronic Radiation Dermatitis
Rarely, acute radiation fails to heal and
consequential-late changes of RT may develop,
which include chronic wounds and skin
necrosis [3]. In contrast, chronic radiation
dermatitis is a true late-stage reaction that
develops months to years after exposure to IR.
The condition may develop in patients who
only experienced minimal acute radiation
dermatitis and so may develop in
near-normal-appearing skin. Unlike acute
radiation dermatitis, chronic radiation
dermatitis is unlikely to self-repair and may
remain indefinitely [3]. The defining features of
the late-stage are fibrosis, atrophy, hypo- or
hyperpigmentary changes and the development
of cutaneous malignancies (Table 4).
Post-inflammatory dyspigmentation is
common, and, depending on the skin type of
the patient and severity of the reaction, may
slowly resolve or worsen over time [3]. The skin
may become xerotic, scaly, and hyperkeratotic.
Significant cutaneous injury is characterized by
persistent dyspigmentation, atrophy, and
telangiectasia (Fig. 4) [3]. Telangiectasia
commonly results from boost dosing, acute
radiation grade 3 injury, and moist
desquamation [17, 18]. With severe cutaneous
injury, there may be permanent loss of nail and
skin appendages, absence of hair follicles and
sebaceous glands with resultant alopecia, and
absent or reduced sweating [3]. Small arteries and
arterioles predisposed to thrombosis or
obstruction may lead to skin breakdown and
Table 3 Common chemotherapeutic agents that induce















Table 4 Clinical manifestations of chronic radiation






























Pain, limited range of
motion, contractures
Secondary malignancy Primarily SCC and BCC
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ulceration [3, 9]. Further, atrophied skin is fragile
and is predisposed to erosions and ulcerations
that are painful and slow to heal [3, 19].
Radiation-induced Fibrosis
When skin and subcutaneous tissue develops
fibrosis, there can be a limited range of motion,
contractures, and pain [3]. Radiation-induced
fibrosis of the skin and subcutaneous tissues
may develop at any RT treatment site; however,
fibrosis most commonly occurs in breast cancer
patients who were formerly treated with a
combination of surgical intervention and RT.
These patients may experience pain, skin
retraction and induration, restricted arm and
neck movement, lymphedema, and skin
necrosis and ulcerations [20]. Boost dosing is
an added risk factor for the development of
fibrosis [21]. Fibrosis in the skin and
subcutaneous tissue is usually diagnosed by
palpation and inspection. Radiation-induced
fibrosis is limited to the region treated with
RT. If tumor recurrence is suspected, MRI may
be obtained to differentiate [22, 23]. However,
biopsy should be obtained to confirm fibrosis.
Secondary Cutaneous Malignancies
Individuals treated with IR are also at risk for
the long-term development of secondary
cutaneous malignancies. Increased risk for skin
cancers may last a lifetime following radiation,
is dose-related, and increases over the patient’s
lifespan [24–26]. Patients who are exposed to
radiation at younger ages are at greater risk for
the development of basal cell carcinoma (BCC)
than those who are exposed as adults
[24, 25, 27, 28]. BCCs that do present
following RT are often more aggressive or
unusual variants [3]. The link between cancer
treatment with RT and the development of
melanoma and other non-melanoma skin
cancers later in life is less clear [24, 28].
PATHOPHYSIOLOGY
Acute Cutaneous Reactions
Radiation-induced tissue injury occurs on a
functional, cellular, and gross level [3]. The
susceptibility of the skin to radiation is due to
the rapid rate of proliferation and maturation of
cells, so that the basal keratinocytes, hair follicle
stem cells and melanocytes are the most
susceptible [29]. RT interferes with normal
production and maturation of epithelial and
hair matrix cells and also leads to the
development of atypical fibroblasts and
cutaneous vasculature [30]. With the first dose
of RT, there is immediate tissue damage,
generation of short-lived free radicals,
irreversible breaks in cellular DNA, and
generation of an inflammatory response
Fig. 4 Chronic radiation dermatitis at the site of radiation
beam entry. The lesion is an 8 9 6 well-demarcated
erythematous atrophic plaque with telangiectasias and
ulceration. Reprinted from The American Journal of
Cardiology, 110, Alison Spiker, Zachary Zinn, William
H. Carter, Roxann Powers, Rodney Kovach,
Fluoroscopy-Induced Chronic Radiation Dermatitis,
1861–1863., Copyright (2012), with permission from
Elsevier
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[3, 31–33]. The early inflammatory response to
radiation is principally caused by a
proinflammatory cytokine cascade (IL-1, IL-3,
IL-5, IL-6, TNF-a), chemokines (IL-8, eotaxin,
CCR receptor), receptor tyrosine kinase, and
adhesions molecules (ICAM-1, VCAM,
E-selectin). These factors create a local
inflammatory reaction of eosinophils and
neutrophils that leads to self-perpetuating
tissue damage and loss of the protective barrier
[34]. Wound healing is impaired by the
destruction of the basal keratinocytes, so that
repeated exposures do not allow time for tissue
or cellular repair. Each additional exposure to
RT results in further direct tissue injury,
inflammation, and impaired epithelial
regeneration, all of which contribute to the
development of acute radiation injury [35].
Chronic Cutaneous Reactions
The development of chronic radiation
dermatitis is intricately related to the cytokine
TGF-b [3, 36]. TGF-b is a regulatory protein that
controls proliferation and differentiation of
many cell types, wound healing, and synthesis
of extracellular matrix proteins in the normal
tissue inflammatory response [37]. Importantly,
TGF-b activates fibroblasts, which are key cells
in the development of late radiation-induced
fibrotic changes [36]. TGF-b has been found to
be upregulated in fibrotic tissue of irradiated
patients, but not in non-irradiated controls [38].
Once the skin has had sufficient opportunity
to ‘‘heal’’ from radiation-induced injury,
long-lasting cellular dysfunction and stromal
changes remain that impair cutaneous integrity
[3, 35]. Permanently atypical fibroblasts may
lead to cutaneous atrophy, contraction, and
fibrosis [39, 40]. These late effects are more
dependent on the type of radiation, area,
volume, fraction size and schedule rather than
total radiation dose [41]. The pathogenesis of
telangiectasia development is unknown;
however, it is thought to be in part due to
acutely damaged microvasculature and
production of platelet-derived growth factor
(PDGF) and fibroblast growth factor by
damaged cells [35]. Leukocyte infiltration at
sites of irradiation is also likely to lead to
atrophy, fibrosis, and necrosis in surrounding
normal tissues [42].
The development of radiation-induced
fibrosis is mediated by inflammation that
begins immediately following RT and
continues for months to years. TNF-a, IL-6,
and IL-1 have been implicated in the
inflammatory response, while TGF-b and PDGF
modulate and enhance fibroblast activity and
encourage production of extracellular matrix
proteins [36, 43–45]. These changes in addition
to radiation-induced alterations of the vascular
system contribute significantly to late toxicity
of RT.
EPIDEMIOLOGY
Skin injuries occur in about 95% of patients
who receive RT [4]. Any body site treated with
RT is susceptible to cutaneous injury; however,
the face, neck, trunk, and extremities are
particularly vulnerable [46]. Patients with
breast cancer, head and neck cancer, lung
cancer, and sarcoma are most often affected
because of the higher radiation doses to the skin
[4, 29, 41, 47]. RT was formerly used by
dermatologists in the treatment of benign
conditions such as acne, eczema and psoriasis
[3]. These patients are also at risk for the
development of chronic radiation dermatitis.
In addition to RT, radiation dermatitis may
occur as a result of accidental or occupational
exposures to radiation [5].
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RISK FACTORS
A variety of factors that increase the risk of
developing acute cutaneous reactions to IR have
been identified (see Table 5). The severity of the
reaction is related to both intrinsic and extrinsic
factors. Extrinsic factors include the total
dosage of radiation, fractioned delivery
schedules, volume of irradiated tissue and the
intrinsic radiosensitivity of the involved tissue
[48]. However, in general, moist intertriginous
skin folds of the body are most susceptible.
These areas include the skin under the breast,
axilla, head and neck, and the groin due to the
‘‘bolus effect’’, i.e. the propensity for higher
doses of radiation to reach the skin folds [49].
Extrinsic Factors
The total dose, dose/fraction, characteristics of
the beam, volume and surface area of exposure
to radiation all influence the degree of tissue
damage [2, 3, 50–53]. For example, the total
radiation dose is an important factor in the
development of skin toxicity. However, the
total dose that leads to cutaneous skin
reactions varies depending on the dosing
schedule. For instance, single doses of
16–22 Gy can result in the development of
skin toxicity. However, if the dose is
fractionated into 2-Gy fractions the total dose
can be increased to 30–40 Gy before skin
toxicity develops [54]. Thus, there is an
increase in radiation tolerance with
hyperfractionated treatments. This strategy
allows for delivery of a higher total radiation
dose with similar cutaneous toxicity to lower
single-dose treatments. Interestingly, the time
before clinical manifestations present is
independent of the radiation dose, and is
actually related to the timing of normal cell
turnover. However, the total dose does affect
the time required for the skin to clinically heal
[55]. The use of boost doses, which
intentionally create overlapping treatment
fields, as well as bolus material are methods of
RT that increase radiation dose and therefore
increase risk of cutaneous reactions [53, 56].
The quality of radiation beam also influences
the development of acute skin toxicity. In
general, modern RT techniques have improved
substantially so that normal tissue should be
spared [57, 58]. New external beam radiation
modalities such as intensity-modulated
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radiotherapy (IMRT) reduce radiation hot spots
in the skin by delivering more homogenous
radiation than traditional wedge beam
radiation. Studies have shown as much as a
20% reduction in the development of moist
desquamation from this modality alone
[59, 60]. IMRT also shows promising reduction
in the incidence of late radiation-induced
cutaneous effects, such as induration and
telangiectasia, in breast cancer patients
[61–63]. Additionally, the type of particle that
is emitted by the radiation source affects the
depth of penetration and extent of damage that
can occur (Table 6). The volume of the area
being treated is proportional to the risk of
developing skin reactions due to the higher
radiation doses needed to treat larger areas.
Certain drugs increase sensitivity to RT, so
that the timing and dose of these agents is
critical [3]. These drugs increase cellular damage
that occurs with RT and hinder tissue repair.
Conventional chemotherapeutic agents as well
as anticancer therapies with EGFR inhibitors
increase the risk of developing severe radiation
dermatitis [64]. Commonly cited agents include
dactinomycin, doxorubicin, methotrexate,
5-fluorouracil, hydroxyurea and bleomycin
[56, 65]. New BRAF inhibitors such as
vemurafenib have also produced severe skin
and oral mucosal reactions when given with
concurrent radiotherapy [66]. In the treatment
of breast cancers, paclitaxel and docetaxel in
conjunction with RT synergistically create
cutaneous damage [67, 68]. Timing of
adjuvant drugs also influences the
development of chronic cutaneous changes to
RT. In an RCT comparing sequential versus
concurrent chemotherapy with RT in breast
cancer patients, the risk for the development of
late subcutaneous fibrosis was greater in those
receiving both therapies at the same time [69].
Tamoxifen is also suspected to increase
subcutaneous fibrosis when used in
conjunction with RT [70].
Intrinsic Factors
Intrinsic factors such as general skin condition,
nutritional status, age, comorbid disease (diabetes
mellitus and connective tissue disorders) and
ethnicity all modulate the risk of acute skin
reactions [71, 72]. Moreover, smoking, actinic
damage, and obesity have also been implicated
[73]. In addition, patients with implants and
Table 6 Radiation particle and effect on skin [11]
Particle
type
Penetration Effect on skin
Alpha Large amount of ionization, but minimal skin
penetration
Not able to penetrate stratum corneum when emitted
Beta Greater penetration than alpha particle, but less
ionization
Shallow penetration of skin
Gamma Low ionization, but high penetration More penetration in skin with damage inversely
proportional to the energy
X-ray Similar to Gamma ray; longer wave length providing
more penetration
Effect on skin is proportional to energy of X-ray
Neutron High penetration due to size and neutral charge Can be lethal; high energy transfer destroying basal
layer of skin leading to necrosis
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breast reconstruction have a higher risk of
radiation dermatitis due to the skin’s inability to
dissipate heat [74, 75]. Furthermore, patientswho
are immunocompromised secondary to HIV
infection who are treated with IR for cancers of
the head and neck, abdomen, or pelvis have an
increased risk of developing mucosal reactions
[76].
Genetics influences the development of
acute cutaneous reactions from radiation,
particularly conditions resulting from
mutations in DNA repair mechanisms. The
most well-known example is ataxia
telangiectasia, a rare autosomal-recessive
disorder that results from mutations in both
ATM genes. Patients with this disorder have a
high propensity to develop severe
complications after RT due to the inability to
repair DNA. An estimated 1% of the population
is heterozygous for the ATM gene [77], which
predisposes patients to develop cutaneous
reactions [78]. Modified treatment protocols
with lower radiation dose and volumes can be
utilized in these patients to avoid skin reactions
and decrease the risk of skin toxicity. Other
conditions that lead to chromosomal breakage
includes Fanconi’s anemia, Bloom syndrome
and xeroderma pigmentosum. Patients with
these conditions develop gaps in skin
fibroblasts after irradiation [79]. Moreover,
specific genetic polymorphisms have been
identified in DNA repair and oxidative stress
response genes that confer a higher risk for
acute skin reactions after radiotherapy [80].
PREVENTION
General Preventive Measures
Prevention of radiation dermatitis is an
important consideration in the pre- and
post-RT period. General measures, such as
maintaining proper skin hygiene by washing
with lukewarm water and mild soaps, and the
use of unscented, lanolin-free water-based
moisturizers, decreases the risk for acute
radiation dermatitis [81, 82]. Avoiding metallic
and/or oil based topical products, wearing
loose-fitting clothes, and avoiding sun
exposure may help prevent post-RT
complications. However, to date, there are few
randomized controlled trials (RCTs) that assess
preventive measures for acute
radiation-induced skin toxicity (Table 7).
Topical moisturizers, gels, emulsions, or
dressings can cause a bolus effect and so
should not be applied shortly before radiation
[83]. Careful positioning of the patient and
appropriate placement of skin shields may
decrease radiation-induced skin problems.
Following RT sessions, exposure to ultraviolet
light in treatment areas and temperature
extremes should be avoided [3]. Patients
undergoing RT treatment should avoid
metallic compounds including magnesium in
talcs and aluminum in antiperspirants [19].
Topical Corticosteroids
Topical corticosteroids have long been used for
the prevention and treatment of RT-induced
skin toxicity due to the underlying
inflammatory pathophysiology. However, the
efficacy of topical corticosteroids in reducing
the frequency and severity of radiation
dermatitis has been evaluated in several small
clinical trials, with inconsistent results [3].
Some studies show no statistically significant
difference between steroid (mometasone
furoate 0.1% cream [84]; 0.2% hydrocortisone
valerate [85]) versus placebo, whereas other
groups demonstrated decreased severity or
frequency of acute radiation dermatitis in the
topical steroid group [86–88]. Advocates of
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corticosteroid use recommend application of
low to medium potency steroid to the
treatment field 1–2 times a day after each RT
session to reduce the severity of acute radiation
dermatitis and decrease the severity of
symptoms, including decreased itching,
irritation, burning, and discomfort. Whether
or not application of corticosteroids during
periods of RT can impact the frequency or
severity of eventual chronic radiation dermatitis
remains to be seen. It is also not known whether
corticosteroids may increase the incidence of
infection, telangiectasia, or skin atrophy [3].
Other Adjuvants
Oral Wobe-Mugus (a proteolytic enzyme
mixture of 100 mg papain, 40 mg trypsin and
40 mg chymotrypsin) has been shown in two
nonblinded RCTs versus no medication to
decrease the odds for developing RT-induced
skin toxicity by as much as 87% [89, 90].
However, dosages and treatment schedule
varied between studies. Other agents,
including aloe vera, trolamine, sucralfate, and
hyaluronic acid, do not have supportive





Management is based principally on the
severity of damaged skin. Patients with grade 1
radiation dermatitis are treated with nonspecific
treatment similar to the aforementioned
general prevention measures. Dry
desquamation can be treated with hydrophilic
moisturizers, while pruritus and irritation can
be treated with low to mid potency steroids.
Grades 2 and 3
With more severe reactions involving moist
desquamation (grades 2 and 3), treatment
Table 7 Preventions and treatments for acute cutaneous skin reactions to radiotherapy
Prevention Level of evidence
Proper skin hygiene Wash with mild soaps and lukewarm water to help maintain skin barrier
Protection of skin from
additional trauma
Use of topical steroids; use before development of radiation dermatitis to slow progression
to radiation dermatitis (Grade B)
Oral Wobe-Mugus can decrease odds of developing radiation dermatitis (Grade C)
Wear loose ﬁtting clothing, avoid sun exposure, avoid metallic based topical products, use
water based lanolin-free moisturizers
Treatment of Level of evidence
Dry desquamation Low- to mid-potency topical steroids; decrease progression and severity of itching, burning and
irritation (Grade C)
Use of hydrophilic moisturizers
Moist desquamation Wound care management with hydrogel and hydrocolloid dressings
Radiation burns Removal of necrotic debris and mesenchymal stem cell injections to area to increase healing
Mesenchymal stem cell injections around lesions to enhance wound healing (Grade D)
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should be directed toward preventing secondary
infection and dressing the areas of moist
desquamation. Dressings are used in moist
desquamation to maintain a wet environment
over de-epithelialized skin, which allows for a
higher rate of wound healing [97]. A variety of
dressings have been employed in the treatment
of these lesions, but results to date are
inconclusive [98–100].
Two types of dressings commonly used in
moist desquamation are hydrogel and
hydrocolloid dressings. Hydrogel dressings do
not adhere to wounds and allow for ease of
cleaning and reapplication. Hydrocolloid
dressings are absorbent, self-adhering, and
can be left in place for several days to
simplify wound care [101]. These dressings
have been shown to speed wound healing and
improve patient comfort, but no
high-powered RCTs exist to date comparing
these treatments [102].
Grade 4
In severe skin reactions to RT (grade 4), there is
significant full-thickness skin necrosis and
ulceration. Treatment requires a
multidisciplinary approach and
discontinuation of RT. In addition, surgical
debridement of necrotic tissues and the
utilization of full-thickness skin grafts or
pedicle flaps may be indicated. These
high-grade cutaneous skin toxicity reactions
can lead to late-consequential changes
including fibrosis and non-healing ulcers,
which have potential for malignant
transformation. Moreover, waves of
inflammation can occur with radiation burns
leading to the need for successive surgical
excisions, reconstruction, and potential need
for amputation [12, 13].
Chronic Cutaneous Reactions
Unlike the majority of cases of acute cutaneous
reactions to RT, chronic radiation dermatitis
and radiation-induced fibrosis are unlikely to be
self-repairing. Management of late cutaneous
reactions of RT is reviewed in Table 8.
Chronic Ulcerations and Wounds
As in acute radiation dermatitis, the care of
ulcerations and wounds resulting from chronic
radiation dermatitis is non-specific and follows
general wound care guidelines. Wound
dressings protect the injured skin from
environmental damage and infection and also
serve to contain wound secretions [3]. Moisture
helps with re-epithelialization of tissue as well
as removal of necrotic tissue and bacteria
[3, 9, 103, 104]. Hydrophilic and lipophilic
creams and ointments may be used alone or
with dressings to enhance barrier function.
Similar to management of moist
desquamation, hydrogel or hydrocolloid
dressings may be utilized.
Chronic ulcers may require careful and
selective debridement. Persistent eschars may be
removed manually, or treated with enzymatic
debridement or autolytic dressings [3]. Chronic,
nonhealing ulcers are poorly vascularized, and
may require surgical intervention with skin flaps
or sometimes staged skin-muscle or axial-pedical
flaps [105]. Less commonly, artificial and
bioengineered skin have been used for
nonhealing ulcerations [104]. Case reports show
that laser therapy with low-intensity helium laser
has benefitted some patients with chronic
ulcerations [106]. For infected or at-risk wounds,
antibacterial agents should be considered.
Silver-based dressings may be effective for this
purpose [3]. Chronic nonhealing ulcers and
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Table 8 Management of chronic radiation dermatitis and radiation-induced ﬁbrosis
Late reaction or complication Management
Ulcers and erosions Non-speciﬁc, follows general wound care guidelines, including
Hydrophilic or lipophilic barrier creams with or without hydrogel or hydrocolloid
dressings
Careful and selective debridement, eschar removal
For infected or at-risk wounds, antibacterial agents as needed and silver-based
dressings
Surgical intervention for nonhealing ulcers with skin ﬂaps, less commonly with
staged skin-muscle or axial-pedical ﬂaps
Grade D
Artiﬁcial or bioengineered skin
Low-intensity helium laser
Fibrosis Supportive measures: physical therapy, massage, and pain management
Grade 2C





Laser therapy with epidermal grafting
Telangiectasias Grade D
Pulse dye laser
Secondary skin cancers and
radiation-induced keratoses
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suspected lesions may need to be biopsied for
histopathologic examination to exclude
secondary skin cancers [3].
Radiation-induced Fibrosis
Radiation-induced fibrosis is one of the most
difficult skin complications to treat [3]. A team
approach with wound care, physical therapy,
and pain management is needed to preserve
quality of life [3]. Physical therapy may include
active and passive range of motion exercises,
which may help to improve range of motion
and reduce contractures. Massage may also be
beneficial [107]. Adequate pain control should
be provided as pain from fibrosis can be
significant.
Pentoxifylline (PTX) may be used alone or in
combinationwith tocopherol (vitaminE) to treat
radiation-induced fibrosis as well as to prevent
pulmonary fibrosis. PTX is a methylxanthine
derivative that is commonly used as an inhibitor
of platelet aggregation, while vitamin E is a
scavenger of reactive oxygen. PTX is thought to
modulate the immune response by increasing
polymorphonuclear leukocyte and monocyte
phagocytic activity, antagonizing TNF-a and
TNF-b [3], decreasing granulocyte–macrophage
colony-stimulating factor and interferon gamma
(IFNc), among other effects [108, 119].
Combination with tocopherol may
downregulate TGF-b expression and may even
reverse alter the abnormal fibroblasts that
perpetuate fibrosis [20, 110–112]. Multiple
small randomized trials have suggested that
PTX and/or tocopherol may reduce fibrosis
[113–116]. However, the results of the largest of
these trials havemet withmixed results. In these
studies, patients treated with PTX in
combination with vitamin E demonstrated
marginal improvement in their condition, but
treatment had little to no benefit over placebo
[115, 116].However, longer-term therapymaybe
an important element in the treatment of
fibrosis. In a study of 44 women with superficial
radiation-induced fibrosis treated with PTX and
tocopherol over a range of 6–48 months,
regression of superficial fibrosis was seen [117].
An average of 68% regression of the
radiation-induced fibrosis required an average
of 24 months of treatment. Those who stopped
treatment prior to 12 months saw a rebound in
thefibrotic area after treatment. PTXandvitamin
E can reverse superficial radiation-induced
fibrosis, but the optimal dose and duration of
therapy are unknown at this time.
Additional therapeutic agents that have been
attempted in the treatment of fibrosis include
superoxide dismutase (SOD), IFNc, hyperbaric
oxygen therapy, and laser therapy with
epidermal grafting [3, 118]. Liposomal SOD is
thought to downregulate TGF-b expression by
myofibroblasts as well as function as an
anti-inflammatory agent and anti-oxidant
[3, 36]. In a clinical trial of 34 patients treated
with 6 intramuscular injections of SOD over a
3-week period, clinical regression of fibrosis was
seen at 2-month follow up [119]. IFNc is an
inflammatory cytokine that is thought to
inhibit collagen production by fibroblasts [3].
Treatment with IFNc in 5 patients over a 1-year
period was shown to be useful in the treatment
of cutaneous fibrosis [120].
Hyperbaric oxygen has been evaluated as a
treatment for radiation-induced fibrosis;
however, there is insufficient evidence to show
efficacy at this time [121–123]. Treatment may
result in less pain, swelling, redness, or
lymphedema, but no effect on fibrosis has
been found [3, 124]. However, hyperbaric
oxygen improves neutrophil function and has
anti-bacterial effects, and thus may be
considered as a guard against infection [3].
Laser therapy with epidermal grafting has
also been explored as a novel approach to the
198 Dermatol Ther (Heidelb) (2016) 6:185–206
treatment of radiation-induced fibrosis. In one
case series, three Vietnamese children who had
developed significant chronic radiation
dermatitis and fibrosis from RT for infantile
hemangiomas were treated with pulse-dye laser
and/or fractional laser with epidermal skin
grafting. The study authors reported skin
softening, increased flexibility, repigmentation
of the skin, and improvement of the
telangiectasias, suggesting that this treatment
modality should be explored further [118].
Quercetin is a bioflavenoid with
anti-inflammatory effects. A study performed
in a mouse model of radiation-induced fibrosis
demonstrated that oral administration reduced
hind limb contracture, collagen expression, and
TGF-b in irradiated skin [125]. However,
quercetin has not yet been tested as a
therapeutic agent for radiation-induced fibrosis
in human trials.
Telangiectasias
Treatments of telangiectasias resulting from
chronic radiation dermatitis are limited.
Treatment with pulse dye laser has been
shown in case series to be beneficial [126]. In a
retrospective study of breast cancer patients
with radiation-induced telangiectasias, all 11
patients experienced clinical improvement with
pulse dye laser, with an average clearance of
72.7% [127].
Secondary Skin Cancers
Squamous cell carcinomas that arise in
radiation fields exhibit aggressive behavior and
more frequently metastasize, so surgical
excision is the preferred modality for
management [3]. Radiation-induced keratoses
are pre-malignant and may be treated with
cryosurgery when localized or with mechanical
destruction with peels, laser, or dermabrasion
when diffuse [3]. Topical 5-fluorouracil,
diclofenac, photodynamic therapy, and
imiquimod have also been used in the
treatment of skin cancers and precancerous
lesions [3, 128, 129].
FUTURE DIRECTIONS
The current advances in reducing cutaneous
reactions have been primarily in the
technological advancements of delivering
increasingly targeted, homogenized RT utilizing
fractionated schedules. The future will combine
these advancements with targeted therapies for
reducing the underlying inflammatory cascade,
such as superoxide dismutase/catalase mimetics
[130], to decrease reactive oxygen species and
interleukin inhibitors. Anti-oxidant properties of
curcumin could be used to reduce radiation skin
toxicity [131]. In addition, stem cell treatments
to replace necrotic tissue after radiation burns
[12] and high-grade radiation dermatitis may
become more readily available options.
CONCLUSIONS
Acute cutaneous skin reactions are common
side effects of RT. Preventive measures for acute
cutaneous skin reactions have proven elusive.
However, progression and severity of reaction
can be mitigated. After acute reactions to RT
develop, they should be treated according to
grade of severity, and RT treatment may be
interrupted if necessary to allow for
re-epithelialization and healing to occur.
Moreover, proper wound management should
be started promptly to decrease healing time
and the risk of secondary infections. Similarly,
therapeutic advancements in the treatment
of chronic radiation dermatitis and
radiation-induced fibrosis have been
promising, however there is still great need for
novel and developing therapies. Supportive care
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and appropriate wound care continue to be
mainstays of treatment at this time.
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